MP74-02 FREE SERUM TESTOSTERONE VERSUS TOTAL TESTOSTERONE AS SURROGATE MARKER FOR THE CLINICAL BENEFIT OF ANDROGEN SUPPRESSION IN PROSTATE CANCER PATIENTS | Publicación